BCL2 and melanoma: This is the case of BRAF mutations in melanoma cells correlating with enhanced levels of immunosuppressive mediators such as IL-6 and IL-10 [42] or anti-apoptotic Bcl-2 and Bcl-xL proteins, regulating the expression of several interleukins, such as IL-8 and IL-1β [43,44].